Public Citizen calls for halt to prasugrel review
This article was originally published in Scrip
Executive Summary
The US FDA's review of Lilly/Daiichi Sankyo 's novel antiplatelet therapy prasugrel (Effient) should be halted until a new Phase III study looking at a lower, safer dose has been performed, Public Citizen's Health Research Group has urged the new FDA commissioner Dr Margaret Hamburg.